These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28143527)

  • 21. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
    Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
    Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune-mediated dormancy: an equilibrium with cancer.
    Teng MW; Swann JB; Koebel CM; Schreiber RD; Smyth MJ
    J Leukoc Biol; 2008 Oct; 84(4):988-93. PubMed ID: 18515327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Interferon-Gamma Paradox in Cancer.
    Zaidi MR
    J Interferon Cytokine Res; 2019 Jan; 39(1):30-38. PubMed ID: 30388040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries.
    Ho PC; Kaech SM
    Curr Opin Immunol; 2017 Jun; 46():38-44. PubMed ID: 28458087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells.
    Kim SJ; Ha GH; Kim SH; Kang CD
    Immunol Invest; 2014; 43(6):517-34. PubMed ID: 24295450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
    Poggi A; Zocchi MR
    Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.
    Kaplan DH; Shankaran V; Dighe AS; Stockert E; Aguet M; Old LJ; Schreiber RD
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7556-61. PubMed ID: 9636188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs.
    Whiteside TL; Mandapathil M; Szczepanski M; Szajnik M
    Bull Cancer; 2011 Feb; 98(2):E25-31. PubMed ID: 21339097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monocytes in the Tumor Microenvironment.
    Ugel S; Canè S; De Sanctis F; Bronte V
    Annu Rev Pathol; 2021 Jan; 16():93-122. PubMed ID: 33497262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enterovirus 71 Proteins 2A and 3D Antagonize the Antiviral Activity of Gamma Interferon via Signaling Attenuation.
    Wang LC; Chen SO; Chang SP; Lee YP; Yu CK; Chen CL; Tseng PC; Hsieh CY; Chen SH; Lin CF
    J Virol; 2015 Jul; 89(14):7028-37. PubMed ID: 25926657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer stem cell-immune cell crosstalk in tumour progression.
    Bayik D; Lathia JD
    Nat Rev Cancer; 2021 Aug; 21(8):526-536. PubMed ID: 34103704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [At the crossroads of cancer].
    Chouaib S
    Bull Cancer; 2013 Jun; 100(6):569-74. PubMed ID: 23735599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
    Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
    Adachi K; Tamada K
    Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation.
    Delfortrie S; Pinte S; Mattot V; Samson C; Villain G; Caetano B; Lauridant-Philippin G; Baranzelli MC; Bonneterre J; Trottein F; Faveeuw C; Soncin F
    Cancer Res; 2011 Dec; 71(23):7176-86. PubMed ID: 22037871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-gamma-dependent immunosuppressive effects of human gingival fibroblasts.
    Shimabukuro Y; Murakami S; Okada H
    Immunology; 1992 Jun; 76(2):344-7. PubMed ID: 1634256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Components of the IFN-gamma signaling pathway in tumorigenesis.
    Blanck G
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):151-8. PubMed ID: 12098930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The pattern recognition receptor-mediated immune tolerance is involved in tumor metastasis].
    Hu ZW; Yang HZ
    Sheng Li Ke Xue Jin Zhan; 2010 Feb; 41(1):5-10. PubMed ID: 21417007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.
    Clements DR; Sterea AM; Kim Y; Helson E; Dean CA; Nunokawa A; Coyle KM; Sharif T; Marcato P; Gujar SA; Lee PW
    J Immunol; 2015 May; 194(9):4397-412. PubMed ID: 25825443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
    Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
    Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.